CDK9 and B-cell chronic lymphocytic leukemia: In particular, flavopiridol was a nonselective CDK9 inhibitor (CDK9/cyclin T1 Ki = 3 nM) which showed in vivo activity in hematologic malignancies (e.g., mantle cell lymphoma, CLL) but was halted due to high toxicity [28].